In line with previous trials that reported new lesions in 26% and 31% (AURA3 and AURA2 studies, retrospectively) of PD cases during osimertinib treatment, a recent retrospective study reported that most patients with an EGFR mutant NSCLC treated with osimertinib experienced their first progression in the initial sites of the disease, particularly in the thorax.2, 14, 19, 20, 21. This evidence concerns the gene MAP3K8 and non-small cell lung carcinoma.